Precision treatment for advanced esophageal cancer based on biomarkers
Part of Cancer, Digestive system clinical trials.
This trial tests if a personalized treatment plan based on specific markers from your tumor can work better than standard chemotherapy for advanced esophageal cancer that has spread. It aims to find the best first treatment for your cancer type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced esophageal squamous cell carcinoma that has spread to other parts of the body.
- You have not received any previous cancer treatment.
- You are generally active and able to care for yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This trial tests a precision medicine approach for people with advanced esophageal cancer that has stopped responding to immunotherapy. The goal is to find better treatments based on each person's tumor biology.
This trial tests whether a personalized treatment plan, chosen using a lab-grown model of your tumor, works better than standard therapy for esophageal cancer that can be surgically removed. It aims to find the most effective drugs for you before surgery.
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Valid MeSH Conditions trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.